Xeno Diagnostics specializes in advanced immunological assays and cell-based evaluations, focusing on therapeutic areas such as immuno-oncology, regenerative medicine, and transplant immunology. Their in-vitro assays are designed to assess immune responses, particularly in drug development, where they evaluate immune cell activation and cytotoxic activity. Techniques such as ELISA, Flow Cytometry, and Luminex™ Technology are employed for endpoint analysis, enabling the screening of drug cytotoxicity on immune cells activated by various stimuli. Additionally, Xeno has developed a validated CD34 stem cell enumeration assay from human umbilical cord blood, showcasing their expertise in regenerative medicine and the evaluation of engineered cells.

In the realm of transplant immunology, Xeno Diagnostics conducts in vitro evaluations of immune responses to potential transplant tissues through Mixed Lymphocyte Reactions. Their assays measure proliferative and cytokine responses using the same advanced technologies, including Flow Cytometry and Luminex™. The company has extensive experience working with various cell types, including human, baboon, bovine, and porcine cells, and has developed assays for assessing antibody-mediated cell cytotoxicity and complement-dependent cytotoxicity. This comprehensive approach positions Xeno Diagnostics as a key player in the development of innovative solutions for immune-related challenges in clinical settings.

United States

Mixed Lymphocyte Reactions are cell proliferation assays. We offer a comprehensive selection of MLRs experiments to test your product.

Xeno Diagnostics

Company Details